HomeCompareDSKE vs PFE

DSKE vs PFE: Dividend Comparison 2026

DSKE yields 24.13% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DSKE wins by $253151977.42M in total portfolio value
10 years
DSKE
DSKE
● Live price
24.13%
Share price
$8.29
Annual div
$2.00
5Y div CAGR
100%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$253151977.47M
Annual income
$251,152,119,271,858.62
Full DSKE calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — DSKE vs PFE

📍 DSKE pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDSKEPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DSKE + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DSKE pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DSKE
Annual income on $10K today (after 15% tax)
$2,050.66/yr
After 10yr DRIP, annual income (after tax)
$213,479,301,381,079.80/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, DSKE beats the other by $213,479,301,358,759.90/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DSKE + PFE for your $10,000?

DSKE: 50%PFE: 50%
100% PFE50/50100% DSKE
Portfolio after 10yr
$126575988.76M
Annual income
$125,576,059,649,058.67/yr
Blended yield
99.21%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

DSKE
Analyst Ratings
5
Buy
1
Hold
Consensus: Buy
Altman Z
1.4
Piotroski
4/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DSKE buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDSKEPFE
Forward yield24.13%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR100%13.2%
Portfolio after 10y$253151977.47M$49.6K
Annual income after 10y$251,152,119,271,858.62$26,258.71
Total dividends collected$253019304.78M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare
Analyst consensusBuyHold

Year-by-year: DSKE vs PFE ($10,000, DRIP)

YearDSKE PortfolioDSKE Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$15,525$4,825.09$9,153$693.39+$6.4KDSKE
2$30,614$14,001.86$8,593$849.25+$22.0KDSKE
3$84,364$51,607.62$8,336$1,066.78+$76.0KDSKE
4$356,099$265,829.26$8,437$1,384.80+$347.7KDSKE
5$2,478,329$2,097,302.87$9,013$1,875.40+$2.47MDSKE
6$29,935,023$27,283,211.12$10,306$2,680.72+$29.92MDSKE
7$648,004,451$615,973,976.73$12,820$4,101.38+$647.99MDSKE
8$25,616,746,869$24,923,382,106.45$17,673$6,826.70+$25616.73MDSKE
9$1,869,026,351,610$1,841,616,432,460.05$27,543$12,591.86+$1869026.32MDSKE
10$253,151,977,468,082$251,152,119,271,858.62$49,560$26,258.71+$253151977.42MDSKE

DSKE vs PFE: Complete Analysis 2026

DSKEStock

Daseke, Inc. provides transportation and logistics solutions with a focus on flatbed and specialized freight in the United States, Canada, and Mexico. It operates through two segments, Flatbed Solutions and Specialized Solutions. The company transports aircraft parts, manufacturing equipment, structural steel, pressure vessels, wind turbine blades, commercial glass, high security cargo, arms, ammunition and explosives, lumber, and building and construction materials, as well as heavy machinery, such as construction, mining, and agriculture. It also offers logistical planning and warehousing services. As of December 31, 2021, it operated 2,623 company-owned tractors and 2,074 independent owned contractors tractors; and 11,266 trailers. Daseke, Inc. was founded in 2008 and is headquartered in Addison, Texas.

Full DSKE Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this DSKE vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DSKE vs SCHDDSKE vs JEPIDSKE vs ODSKE vs KODSKE vs MAINDSKE vs JNJDSKE vs MRKDSKE vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.